RARE — Ultragenyx Pharmaceutical Inc. stock price, charts and financials

QT33Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
14.50
+1.62+12.58%
OverviewShort InterestFilings
RAREQT33Ultragenyx Pharmaceutical Inc.·NASDAQ
14.50+12.58%
Filing
Up 12.6% — Filed an 8-K material-event report (2026-09-17) — details in the filing.
Medium confidence
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
MESO+3.19%$14.87FTRE+1.55%$20.28NKTR+1.45%$68.36GHRS+3.50%$28.72RAPP+1.35%$41.95AGIO+2.00%$33.61ZBIO-1.08%$31.97GPCR-1.13%$35.10
Snapshot
Index-P/E-EPS (ttm)-5.84Insider Own4.11%Shs Outstand98.49MPerf Week0.69%
Market Cap1.43BForward P/E-EPS next Y-0.70Insider Trans-0.91%Shs Float94.61MPerf Month-43.11%
Enterprise Value2.34BPEG-EPS next Q-0.65Inst Own-Short Float18.12%Perf Quarter-46.12%
Income-586.00MP/S1.99EPS this Y31.56%Inst Trans-Short Ratio7.32Perf Half Y-29.13%
Sales717.00MP/B-EPS next Y82.48%ROA-46.39%Short Interest17.14MPerf YTD-36.96%
Book/sh-2.88P/C4.89EPS next 5Y-ROE392.35%52W High39.89 -63.65%Perf Year-50.81%
Cash/sh2.96P/FCF-EPS past 3/5Y-ROIC-53.48%52W Low12.73 13.90%Perf 3Y-64.98%
Dividend Est.-EV/EBITDA-Sales past 3/5Y22.85% 19.95%Gross Margin83.12%Volatility5.90% 4.97%Perf 5Y-85.68%
Dividend TTM-EV/Sales3.26EPS Y/Y TTM7.15%Oper. Margin-73.77%ATR (14)1.50Perf 10Y-78.69%
Dividend Ex-Date-Quick Ratio1.56Sales Y/Y TTM28.04%Profit Margin-81.79%RSI (14)28.06Recom2.24
Dividend Gr. 3/5Y-Current Ratio1.73EPS Q/Q23.08%SMA20-27.73%Beta0.32Target Price25.00
Payout0.00%Debt/Eq0.11Sales Q/Q28.92%SMA50-41.18%Rel Volume3.48Prev Close12.88
Employees1,371LT Debt/Eq-16.37EarningsNov 03SMA200-42.54%Avg Volume3.49MPrice14.50
IPO DateJan 31, 2014Option/ShortYes / YesEPS/Sales Surpr.26.09% 16.89%Net Debt/EBITDA-2.28Volume12,132,188Change12.58%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-04-26ReiteratedBarclaysOverweight$43 → $32
Sep-03-26ReiteratedMorgan StanleyOverweight$18
Sep-03-26ReiteratedJefferiesBuy$28
Sep-03-26ReiteratedCantor FitzgeraldOverweight$33
Sep-03-26ReiteratedWedbushNeutral$30 → $23
Sep-03-26ReiteratedRBC CapitalOutperform$40 → $19
Sep-03-26ReiteratedCanaccord GenuityBuy$37
Sep-03-26ReiteratedH.C. WainwrightBuy$50 → $25
Sep-03-26ReiteratedWells FargoOverweight$50 → $18
Sep-03-26ReiteratedRobert W. Baird$40 → $16
Latest News· Times ET
Today
Today11:48AM
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)globenewswire.com
10:41AM
US FDA approves Ultragenyx's gene therapy for rare disorderreuters.com
Sep-15-26
Sep-15-2601:16PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREglobenewswire.com
Sep-08-26
Sep-08-2601:32PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREglobenewswire.com
Sep-04-26
Sep-04-2609:08PM
Why Ultragenyx Pharmaceutical (RARE) Is Down 40.3% After Angelman Trial Failure And Cost-Cut PlanYahoo
09:57AM
Goldman Sachs Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $19Benzinga
Sep-03-26
Sep-03-2608:36AM
Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report?zacks.com
08:25AM
RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goalszacks.com
08:17AM
QUICK SPARK: Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A Targetbenzinga.com
05:10AM
Ultragenyx Forced To Cut Costs After Disappointing Phase 3 Resultsbenzinga.com
04:05AM
Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More247wallst.com
03:46AM
Ultragenyx Stock Sinks 47% on Drug Trial Failure. Why Wall Street Isn't Giving Up Yet.barrons.com
02:32AM
Ultragenyx shares crater after Angelman syndrome drug fails late-stage trialreuters.com
Sep-02-26
Sep-02-2612:19PM
Ultragenyx's rare disease drug fails in late-stage trial; shares plungereuters.com
12:01PM
Ultragenyx Announces Phase 3 Aspire results in Angelman Syndromeglobenewswire.com
Company

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue717673560——————
Cost of Goods Sold Incl. D&A12110977——————
Gross Profit596564484——————
Selling, General and Administrative Excl. Other352349322——————
Research and Development773750698——————
Other Operating Expense00-1——————
Operating Income-529-535-536——————
Interest Expense766263——————
Unusual Expense
—————————
Non-Operating Income (Expense)222631——————
Net Income Before Taxes-583-571-568——————
Income Taxes442——————
Consolidated Net Income-586-575-569——————
Net Income From Continuing Operations-586-575-569——————
Net Income-586-575-569——————
EPS (Recurring)-5.84-5.83-6.29——————
EPS (Basic, Before Extraordinaries)-5.84-5.83-6.29——————
EPS (Diluted)-5.84-5.83-6.29——————
EBITDA-473-474-469——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio2.063.386.84——————
Gross Margin83.1283.8086.43——————
Operating Margin-73.78-79.49-95.71——————
Net Margin-81.73-85.44-101.61——————
Shares Outstanding1029991——————
Market Capitalization1,4792,2773,828——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$40.09$32.40$24.71$17.02$9.33● Close Price0.00M0.63M1.26M1.90M2.53MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Huizenga Theodore AlanSVP, Chief Accounting OfficerSep 15 '26Sale13.571,28317,41067,863Sep 15
Huizenga Theodore AlanSVP, Chief Accounting OfficerSep 03 '26Sale13.991612,25269,146Sep 08
Horn HowardChief Financial OfficerAug 03 '26Sale24.924,696117,02496,295Aug 04
Parschauer Karah HerdmanEVP and Chief Legal OfficerAug 03 '26Sale24.921,90047,34892,562Aug 04
Horn HowardChief Financial OfficerJul 01 '26Sale33.134,698155,645100,991Jul 06
Sanders Corazon (Corsee) D.DirectorJun 15 '26Sale25.052,00050,10021,095Jun 15
Parschauer Karah HerdmanEVP and Chief Legal OfficerJun 15 '26Sale24.621,89946,75394,462Jun 15
Horn HowardChief Financial OfficerJun 01 '26Sale23.774,653110,602105,689Jun 01
SULIMAN SHEHNAAZDirectorMay 18 '26Sale25.125,740144,18927,951May 18
Crombez EricEVP and Chief Medical OfficerMay 05 '26Sale24.963448,586111,189May 06
Horn HowardChief Financial OfficerMay 01 '26Sale24.904,683116,607110,342May 04
Horn HowardChief Financial OfficerApr 01 '26Sale20.974,68398,20380,351Apr 02
Parschauer Karah HerdmanEVP and Chief Legal OfficerMar 10 '26Sale22.673,50879,52666,820Mar 10
Parschauer Karah HerdmanEVP and Chief Legal OfficerMar 06 '26Sale21.406,018128,78570,328Mar 10
Horn HowardChief Financial OfficerMar 03 '26Sale22.401,63536,62485,034Mar 03
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.